Holen Sie sich die Stockscreener-App
10.74
0.66%
0.07
Vorhandelsmarkt:
10.76
0.02
+0.19%
Kura Oncology Inc Aktie (KURA) Neueste Nachrichten
Insider Sell: Faheem Hasnain Sells 10,000 Shares of Kura Oncology Inc (KURA) - GuruFocus
Kura Oncology stock maintains Market Outperform rating at Citizens By Investing.com - Investing.com Canada
Kura Oncology, Inc. (KURA) Fundamental Analysis - Meyka
Kura Oncology (KURA) Reports Promising AML Trial Results - GuruFocus
Kura Oncology, Kyowa Kirin reveal Komsifti combo data for AML - Seeking Alpha
Kura Oncology, Kyowa Kirin Report 'Encouraging' Drug Combo Data to Treat Acute Myeloid Leukemia - marketscreener.com
Kura Oncology & Kyowa Kirin announce positive Komzifti combination data for acute myeloid - marketscreener.com
Kura Oncology completes first U.S. commercial sale of KOMZIFTI - MSN
Kura Oncology (KURA) Reveals Positive Leukemia Treatment Data - GuruFocus
Kura Oncology and Kyowa Kirin Report Combination Data for KOMZIFTI™ (Ziftomenib) with Venetoclax and Azacitidine in Newly Diagnosed and Relapsed/Refractory AML - The Manila Times
Kura Oncology and Kyowa Kirin Report Combination Data for KOMZIFTI with Venetoclax and Azacitidine in Newly Diagnosed and Relapsed/Refractory AML - marketscreener.com
Kura Oncology, Inc. $KURA Shares Sold by Walleye Capital LLC - MarketBeat
What analysts say about Kura Oncology Inc stockStock Buy Signals & Free Real-Time Trading Alerts Every Day - earlytimes.in
Why The Narrative Around Kura Oncology Is Shifting After Komzifti’s FDA Breakthrough - Yahoo Finance
Kura Oncology stock rating reiterated at Market Outperform by Citizens - Investing.com Canada
Franklin Resources Inc. Decreases Stake in Kura Oncology, Inc. $KURA - MarketBeat
FDA approved five NMEs in November - biocentury.com
Blood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection Points - The Malaysian Reserve
Kura Oncology (NASDAQ:KURA) Trading Up 7.3%What's Next? - MarketBeat
Kura Oncology: A Cautious Buy (NASDAQ:KURA) - Seeking Alpha
Kura Oncology to Host Virtual Investor Event to Discuss Data Presented at ASH 2025 on Triplet Combination of Ziftomenib (KOMZIFTI®) with Venetoclax and Azacitidine in Newly Diagnosed and Relapsed/Refractory Acute Myeloid Leukemia - The Manila Times
Kura Oncology (NASDAQ: KURA) plans Dec. 8 webcast on ASH 2025 AML triplet study data - Stock Titan
Kura Oncology completes first commercial sale of leukemia drug By Investing.com - Investing.com Canada
Geode Capital Management LLC Purchases 211,470 Shares of Kura Oncology, Inc. $KURA - MarketBeat
Kura Oncology Announces First U.S. Sale of KOMZIFTI - MSN
Kura Oncology (KURA) Is Down 7.2% After First KOMZIFTI Sale Triggers $135M Milestone Payment - simplywall.st
Kura Oncology: Expect Volatility Following Ziftomenib Phase 1b Data (NASDAQ:KURA) - Seeking Alpha
Kura Oncology, Inc. Completes Collaboration and License Agreement with Kyowa Kirin - marketscreener.com
Kura Oncology Expects $135 Million Milestone Payment for First US Sale of Komzifti - marketscreener.com
Kura Oncology announces first US sale of KOMZIFTI, triggering $135 million payment - Investing.com Nigeria
Kura Oncology (KURA) Secures $135 Million Milestone with KOMZIFT - GuruFocus
Kura Oncology announces first US sale of KOMZIFTI, triggering $135 million payment By Investing.com - Investing.com South Africa
Kura Oncology completes first commercial sale of leukemia drug - Investing.com
First U.S. commercial sale of Komzift triggers $135 million milestone payment to Kura Oncology - marketscreener.com
First U.S. Commercial Sale of KOMZIFTI™ Triggers $135 Million Milestone Payment to Kura Oncology Under Collaboration and License Agreement with Kyowa Kirin - The Manila Times
Kura Oncology (Nasdaq: KURA) to receive $135M as KOMZIFTI launches in U.S. market - Stock Titan
First U.S. Commercial Sale of KOMZIFTI™ Triggers $135 - GlobeNewswire
How Kura Oncology Inc. stock trades during market volatilityRate Hike & Daily Growth Stock Investment Tips - Newser
How geopolitical tensions affect Kura Oncology Inc. stockWeekly Stock Report & Technical Confirmation Trade Alerts - Newser
How rising interest rates impact Kura Oncology Inc. stock - Newser
Is Megatherm Induction Limited Stock a Strong Buy According to Wall StreetLarge Cap Stability Picks & Free Unlock Stock Analysis - earlytimes.in
Rhenman & Partners Asset Management AB Boosts Stake in Kura Oncology, Inc. $KURA - MarketBeat
Magnetar Financial LLC Buys 64,345 Shares of Kura Oncology, Inc. $KURA - MarketBeat
Foresite Capital Management IV LLC Has $4.71 Million Holdings in Kura Oncology, Inc. $KURA - MarketBeat
KOMZIFTI™ (ziftomenib) Added to National Comprehensive Cancer Network® (NCCN) Guidelines for Acute Myeloid Leukemia (AML) - The Manila Times
Kura Oncology’s leukemia drug added to NCCN treatment guidelines By Investing.com - Investing.com Australia
Kura Oncology’s leukemia drug added to NCCN treatment guidelines - Investing.com UK
Kura Oncology stock rises after KOMZIFTI added to NCCN treatment guidelines - Investing.com Canada
Kura Oncology and Kyowa Kirin's KOMZIFTI™ Approved and Included in NCCN Guidelines for Treatment of Relapsed/Refractory AML with NPM1 Mutation - Quiver Quantitative
KOMZIFTI™ (ziftomenib) Added to National Comprehensive - GlobeNewswire
Kura Oncology (NASDAQ: KURA) KOMZIFTI Named NCCN Category 2A Option for R/R NPM1 AML - Stock Titan
Interesting KURA Put And Call Options For July 2026 - Nasdaq
Kura Oncology (KURA) Is Up 8.1% After FDA Approval of KOMZIFTI for NPM1-Mutated AML – What's Changed - Yahoo Finance
Barclays Remains a Buy on Kura Oncology (KURA) - The Globe and Mail
Barclays Raises Price Target for Kura Oncology (KURA) to $28 | K - GuruFocus
Barclays Maintains Kura Oncology (KURA) Overweight Recommendation - MSN
KURA Stock Rises Pre-Market After Receiving Milestone Payment Related To Cancer Drug Development Agreement - MSN
Is Kura Oncology Inc a good long term investmentMarket Entry Points & Free Exceptional Risk Adjusted Gains - earlytimes.in
Why The Narrative Around Kura Oncology Is Shifting After FDA Approval and Analyst Upgrades - Yahoo Finance
0.45%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):